Two Chemical Giants, Two Totally Different Stories About the Same Approach
A potential BASF takeover of Evonik has moved from market speculation into a formally acknowledged transaction discussion, but the two companies are describing the same approach in notably different terms. BASF calls the discussions “exploratory,” while Evonik has characterized the proposal as a “non-binding approach,” and the €10.3 billion offer has reportedly been rejected as too low.
The situation matters well beyond corporate ownership. A combination would bring together two of Germany's largest chemical businesses at a time when European producers face high energy costs, weak demand and increasingly aggressive global competition. For specialty chemical buyers, any major portfolio consolidation could eventually affect product strategies, manufacturing footprints, capacity allocation and supplier relationships.
BASF and Evonik Are Describing Different Stages of the Same Process
BASF publicly confirmed on September 25 that it was holding exploratory discussions with Evonik and RAG-Stiftung about a possible takeover. The company stressed that the course and outcome of the talks remained open and said it evaluates acquisitions that strengthen its core businesses, provide strategic fit and support profitable growth.
Evonik's description was more specific. The company confirmed that it had received a non-binding approach from BASF regarding a potential takeover, establishing that BASF had moved beyond general strategic interest and made an actual proposal.
That distinction is important for chemical-market participants. An exploratory discussion does not guarantee a transaction, while a non-binding approach can still be revised, rejected or abandoned before a formal offer reaches shareholders.
The €10.3 Billion Proposal Has Already Hit Resistance
The talks have progressed further since the initial announcements. Reuters reported that Evonik rejected a BASF offer valued at approximately €10.3 billion, equivalent to about €22.15 per share, because it considered the bid too low.
That does not necessarily end the process. BASF could reconsider its valuation, adjust the proposal or decide that the expected strategic benefits do not justify a higher price.
The development also shows why the terminology around the deal matters. BASF has not announced a binding acquisition agreement, while Evonik's rejection of the reported proposal leaves the transaction in a negotiation stage rather than a completed takeover process.
Why RAG-Stiftung Holds the Key Stake
The most important ownership factor is RAG-Stiftung. The foundation currently holds approximately 43.8% of Evonik's issued shares and confirmed that BASF had contacted it regarding a potential voluntary public takeover offer.
That stake gives RAG-Stiftung an unusually important position in any potential transaction. BASF is therefore not dealing only with Evonik's management and shareholders in the broader market. It also has to engage with an institutional shareholder that controls a substantial block of the company.
The foundation's position has become even more significant after it indicated that it could potentially sell its entire Evonik stake. Reuters reported on September 30 that RAG-Stiftung may sell its holding, although the foundation did not disclose a specific reason for considering such a move.
For BASF, this creates both an opportunity and a constraint. A transaction involving such a large shareholder could materially influence the ownership structure, but agreement on valuation and strategic conditions remains essential.
Why BASF Would Want Evonik's Specialty Portfolio
The strategic rationale is closely linked to the structure of both companies. Evonik has a large specialty chemicals portfolio spanning high-value materials and ingredients, while BASF has a much broader chemicals platform covering chemicals, materials, industrial solutions, nutrition and care as well as other businesses.
ICIS reported that acquiring Evonik would strengthen BASF's position in specialty chemicals. The two companies generated approximately €60 billion and €14 billion in sales respectively in 2025, illustrating the scale of the potential combination.
For BASF, an acquisition could potentially add specialty products, technologies and customer relationships without requiring the company to build equivalent positions organically. It could also provide opportunities to combine manufacturing, procurement and distribution activities.
However, those potential benefits need to be balanced against the purchase price, integration complexity and regulatory scrutiny that would accompany a major European chemical-sector transaction.
Europe's Chemical Industry Is Driving the Consolidation Debate
The timing of the approach is significant. European chemical manufacturers have faced persistent pressure from high energy costs, subdued demand and competition from producers with cheaper feedstocks and energy.
The industry has already seen major ownership changes and portfolio restructuring as companies seek to concentrate capital on higher-value businesses. The potential BASF-Evonik transaction fits into that broader pattern, although its eventual structure and outcome remain uncertain.
BASF has explicitly said its acquisition strategy focuses on strengthening core businesses, strategic fit, profitable growth and value creation.
For specialty chemicals, this approach can encourage companies to prioritize businesses with differentiated technology, strong customer relationships and better margins over commodity-oriented production.
What a Combined Portfolio Could Mean for Chemical Buyers
Customers would not necessarily see immediate changes if a transaction were completed. Existing contracts, specifications and production assets would continue operating through the integration period.
Over the longer term, however, portfolio decisions could become important. A combined company could review overlapping products, production sites, distribution networks and research programmes to determine where resources should be concentrated.
Potential areas for buyers to monitor include:
Product portfolio changes: Overlapping specialty products could be reviewed after integration.
Manufacturing footprint: Plants may be assessed for cost competitiveness, utilization and strategic importance.
Capacity allocation: Production could shift between facilities depending on economics and regional demand.
Contract structures: Customer agreements could eventually move to new commercial entities or business units.
R&D priorities: Combined research capabilities could redirect investment toward higher-growth specialty applications.
Supplier qualification: Buyers may need to monitor any changes in manufacturing locations or product specifications.
None of these changes should be treated as confirmed consequences of the current talks. They are the areas procurement teams would normally watch if a transaction progresses.
The Specialty Chemicals Market Could See More Consolidation
The proposed transaction arrives as European chemical companies continue to reassess where they can compete globally. Specialty chemicals can offer more differentiated economics than commodity products, but they still face pressure from energy costs, Asian capacity growth and changing customer requirements.
A larger combined portfolio could potentially give BASF greater scale across specialty applications. At the same time, integration could create pressure to rationalize assets where the two businesses have overlapping capabilities.
That makes the deal relevant to competing chemical producers as well. Rivals may respond by reviewing their own portfolios, pursuing acquisitions or divesting businesses that no longer fit their strategic priorities.
The result could be a more concentrated European specialty chemicals market even if the BASF-Evonik transaction itself does not ultimately close.
RAG-Stiftung's Decision Is Only One Part of the Equation
The 43.8% RAG-Stiftung stake makes the foundation a critical shareholder, but it does not mean that a takeover is automatic if the foundation supports it. A transaction would still involve valuation, corporate governance, regulatory requirements and broader shareholder considerations.
North Rhine-Westphalia has also emphasized the importance of Evonik's independence and employment base. Reuters reported that the state government raised concerns about protecting jobs and Evonik's independence following the takeover approach.
That adds another dimension to the discussions because Evonik is deeply connected to the Ruhr region's industrial economy. A major ownership change could therefore attract attention beyond investors and chemical customers.
The combination of shareholder influence, valuation differences and regional industrial interests means the next phase could be more complicated than simply agreeing on a purchase price.
What Specialty Chemical Buyers Should Watch Now
For procurement managers, the most useful approach is to separate confirmed developments from possible future changes. BASF has confirmed exploratory discussions, Evonik has confirmed a non-binding approach and the reported €10.3 billion proposal has been rejected as too low.
Beyond those facts, buyers should monitor several indicators:
Any revised BASF proposal: A higher offer would indicate whether the strategic rationale remains strong enough to justify additional valuation.
RAG-Stiftung's position: Its 43.8% holding makes its actions particularly important to the ownership outlook.
Evonik's strategic response: The company could pursue alternatives that strengthen its independence or improve shareholder value.
Regulatory developments: A completed transaction would require scrutiny of competition and market concentration.
Portfolio announcements: Any planned divestments, plant changes or business combinations could eventually affect supply chains.
Customer communication: Buyers should watch for changes to legal entities, product manufacturing locations or commercial terms if negotiations progress.
For now, there is no completed takeover to incorporate into sourcing decisions.
A Potential Deal That Could Reshape European Specialty Chemicals
The BASF-Evonik approach illustrates how quickly Europe's chemical-sector structure can become a strategic question. BASF sees potential value in exploring a takeover, Evonik has rejected the reported offer as insufficient and RAG-Stiftung's 43.8% stake makes the foundation a central shareholder in the process.
Whether the parties can bridge the valuation gap remains unresolved. But even without a completed transaction, the approach signals that Europe's major chemical companies are actively reassessing scale, portfolio strength and competitive positioning.
Found this useful?
